Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

NCT06876532 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Intestinal Neuroendocrine Tumor

Interventions

OTHER: Additional blood tests (CRP and serum albumin) and data collection.

Sponsor

Institut Claudius Regaud